Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma
Papillary thyroid carcinoma is the most common primary thyroid cancer. Most frequently treated with surgical resection, some cases require radioactive iodine (RAI) therapy. Studies have suggested that there is an increase in second primary malignancy after RAI therapy amongst thyroid cancer survivor...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2020-03-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/505686 |
| _version_ | 1819229289224077312 |
|---|---|
| author | Arwa Alsaud Shehab Mohamed Mohamed A. Yassin Amr Ashour Khaldun Obeidat Bahjat Azrieh |
| author_facet | Arwa Alsaud Shehab Mohamed Mohamed A. Yassin Amr Ashour Khaldun Obeidat Bahjat Azrieh |
| author_sort | Arwa Alsaud |
| collection | DOAJ |
| description | Papillary thyroid carcinoma is the most common primary thyroid cancer. Most frequently treated with surgical resection, some cases require radioactive iodine (RAI) therapy. Studies have suggested that there is an increase in second primary malignancy after RAI therapy amongst thyroid cancer survivors including acute myeloid leukemia (AML) as an infrequent cancer related to RAI therapy; it has a higher relative risk ratio in patients on higher doses of radiation exposure. We would like to report a 30-year-old lady who was diagnosed with papillary thyroid carcinoma. She underwent total thyroidectomy and received a low-dose RAI 131I therapy at a dose of 150 mCi, after which she developed therapy-related AML. Here we would like to highlight the association of AML with low-dose RAI as an infrequent cause of a second primary tumor compared to high doses. |
| first_indexed | 2024-12-23T11:10:48Z |
| format | Article |
| id | doaj.art-e5358dc091ed4846b838451bd7f24c1c |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-23T11:10:48Z |
| publishDate | 2020-03-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-e5358dc091ed4846b838451bd7f24c1c2022-12-21T17:49:21ZengKarger PublishersCase Reports in Oncology1662-65752020-03-0113120721110.1159/000505686505686Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid CarcinomaArwa AlsaudShehab MohamedMohamed A. YassinAmr AshourKhaldun ObeidatBahjat AzriehPapillary thyroid carcinoma is the most common primary thyroid cancer. Most frequently treated with surgical resection, some cases require radioactive iodine (RAI) therapy. Studies have suggested that there is an increase in second primary malignancy after RAI therapy amongst thyroid cancer survivors including acute myeloid leukemia (AML) as an infrequent cancer related to RAI therapy; it has a higher relative risk ratio in patients on higher doses of radiation exposure. We would like to report a 30-year-old lady who was diagnosed with papillary thyroid carcinoma. She underwent total thyroidectomy and received a low-dose RAI 131I therapy at a dose of 150 mCi, after which she developed therapy-related AML. Here we would like to highlight the association of AML with low-dose RAI as an infrequent cause of a second primary tumor compared to high doses.https://www.karger.com/Article/FullText/505686leukemiaradioiodinethyroid cancer |
| spellingShingle | Arwa Alsaud Shehab Mohamed Mohamed A. Yassin Amr Ashour Khaldun Obeidat Bahjat Azrieh Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma Case Reports in Oncology leukemia radioiodine thyroid cancer |
| title | Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma |
| title_full | Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma |
| title_fullStr | Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma |
| title_full_unstemmed | Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma |
| title_short | Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma |
| title_sort | acute myeloid leukemia after low dose radioiodine therapy for papillary thyroid carcinoma |
| topic | leukemia radioiodine thyroid cancer |
| url | https://www.karger.com/Article/FullText/505686 |
| work_keys_str_mv | AT arwaalsaud acutemyeloidleukemiaafterlowdoseradioiodinetherapyforpapillarythyroidcarcinoma AT shehabmohamed acutemyeloidleukemiaafterlowdoseradioiodinetherapyforpapillarythyroidcarcinoma AT mohamedayassin acutemyeloidleukemiaafterlowdoseradioiodinetherapyforpapillarythyroidcarcinoma AT amrashour acutemyeloidleukemiaafterlowdoseradioiodinetherapyforpapillarythyroidcarcinoma AT khaldunobeidat acutemyeloidleukemiaafterlowdoseradioiodinetherapyforpapillarythyroidcarcinoma AT bahjatazrieh acutemyeloidleukemiaafterlowdoseradioiodinetherapyforpapillarythyroidcarcinoma |